Advertisement
open access
Medical Conferences

Medical Conferences

  • Conference Reports
    • 2023 Medicom Conference Planning
  • Disease Areas
  • Other Medical News
  • Podcast
  • Videos
  • Education
  • About
    • Vacancies

Tag: Colorectal Cancer

Combination botensilimab plus balstilimab demonstrates promising activity in heavily pre-treated MSS CRC

Presented By
Prof. Anthony El-Khoueiry, Norris Comprehensive Cancer Center, CA, USA
Trial
Phase 1, C-800
Conference
ASCO GI 2023

17 March, 2023 09:06

Mutation-based selection to identify patients suitable for panitumumab treatment

Presented By
Dr Kohei Shitara, National Cancer Center Hospital East, Japan
Trial
Phase 3, PARADIGM
Conference
ASCO GI 2023

17 March, 2023 09:01

SUNLIGHT trial meets primary endpoint in refractory metastatic CRC

Presented By
Prof. Josep Tabernero, Val d’Hebron University Hospital and Institute of Oncology, Spain
Trial
Phase 3, SUNLIGHT
Conference
ASCO GI 2023

17 March, 2023 08:45

Does cell-free DNA influence MRD testing in post-operative colon cancer?

Presented By
Dr Stacey Cohen, University of Washington, WA, USA
Conference
ASCO GI 2023

17 March, 2023 08:41

Computer-aided colonoscopies improved adenoma detection rates

Presented By
Dr Michiel Maas, Raboud UMC, the Netherlands
Conference
UEGW 2022

2 December, 2022 09:44

Benefit of colon cancer screening with colonoscopy lower than anticipated

Presented By
Prof. Michael Bretthauer, Oslo University, Norway
Trial
Phase 3, NordICC
Conference
UEGW 2022

2 December, 2022 09:41

Screening-detected colorectal cancers may have superior surgical outcomes

Presented By
Dr Jannie Dressler, Bispebjerg Hospital, Denmark
Conference
UEGW 2022

2 December, 2022 09:37

UEGW 2022 Highlights Podcast

Presented By
Robert van den Heuvel, Medicom
Conference
UEGW 2022

13 October, 2022 22:43

Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer  

Presented By
Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan
Trial
Phase 3, PARADIGM
Conference
ASCO 2022

5 August, 2022 15:19

Triplet chemotherapy beats doublet chemotherapy in colorectal cancer liver metastases

Presented By
Prof. Cornelis Punt, University Medical Center Utrecht, the Netherlands
Trial
Phase 3, CAIRO5
Conference
ASCO 2022

5 August, 2022 15:11

NIPICOL: New data on optimal ICI treatment duration in MSI/dMMR mCRC

Presented By
Dr Romain Cohen, Sorbonne University, France
Trial
Phase 2, NIPICOL
Conference
ASCO GI 2022

21 March, 2022 10:30

DESTINY-CRC01: Maintained efficacy of T-DXd in mCRC

Presented By
Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan
Trial
Phase 2, DESTINY-CRC01
Conference
ASCO GI 2022

21 March, 2022 10:26

Key updates in colorectal cancer screening

Presented By
Dr Robin Mendelsohn, Memorial Sloan Kettering Cancer Center, NY, USA
Conference
ASCO GI 2022

21 March, 2022 10:25

Impact of COVID-19 on screening for colorectal cancer

Presented By
Dr John Carethers, University of Michigan, MI, USA
Conference
ASCO GI 2022

21 March, 2022 10:23

Nivolumab plus standard-of-care does not meet primary endpoint for mCRC

Presented By
Dr Heinz-Josef Lenz, USC Norris Comprehensive Cancer Center, CA, USA
Trial
Phase 3, CheckMate 9X8
Conference
ASCO GI 2022

21 March, 2022 10:21

No benefit of additional oxaliplatin in elderly patients with mCRC

Presented By
Dr Tetsuya Hamaguchi, National Cancer Center, Japan
Trial
Phase 3, JCOG1018, RESPECT
Conference
ASCO GI 2022

21 March, 2022 10:19

Analysis of metastasectomy in CRC reveals benefits and disparities

Presented By
Dr Jude Khatib (University of Texas, TX, USA
Conference
ASCO GI 2022

21 March, 2022 10:12

EPOCH trial: Subgroup analyses and additional endpoints for TARE plus chemo

Presented By
Dr William Harris, Seattle Cancer Care Alliance, WA, USA
Trial
Phase 3, EPOCH
Conference
ASCO GI 2022

21 March, 2022 10:09

ASCO GI 2022 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
ASCO GI 2022

8 February, 2022 12:37

Immune chemo-sensitisation looks promising in microsatellite-stable mCRC

Presented By
Dr Filippo Pietrantonio, Istituto Nazionale dei Tumori di Milano, Italy & Dr Chiara Cremolini, Azienda Ospedaliero-Universitaria Pisana, Italy
Trial
Phase 2, MAYA & AtezoTRIBE
Conference
ESMO 2021

19 November, 2021 09:42

Adagrasib shows promising clinical activity in heavily pretreated KRAS-mutated CRC

Presented By
Dr Jared Weiss, University of North Carolina at Chapel Hill, NC, USA
Trial
Phase 1/2, KRYSTAL-1
Conference
ESMO 2021

19 November, 2021 09:42

Pembrolizumab benefits survival in MSI-H/dMMR metastastic colorectal cancer

Presented By
Prof. Thierry André, Sorbonne University, France
Trial
Phase 3, KEYNOTE 177
Conference
ASCO 2021

12 August, 2021 23:32

Panitumumab added to 5-FU/LV effective as maintenance therapy in patients with mCRC

Presented By
Prof. Dominik Modest, Charité Universitätsmedizin Berlin, Germany
Trial
Phase 3, PANAMA
Conference
ASCO 2021

12 August, 2021 22:34

Trastuzumab-deruxtecan showed promising activity in patients with HER2-expressing mCRC

Presented By
Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan
Trial
Phase 2, DESTINY-CRC01
Conference
ASCO 2021

12 August, 2021 21:10

ECCO 2021 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
ECCO 2021

10 August, 2021 08:17

Risk of colorectal cancer is detected by low-pass whole genome sequencing

Presented By
Dr Ibrahim Al Bakir, Queen Mary University of London, UK
Conference
ECCO 2021

2 July, 2021 19:03

First-line pembrolizumab shows superior PFS in MSI-H/dMMR mCRC

Presented By
Dr Kai-Keen Shiu, University College London Hospitals NHS Foundation Trust, UK
Trial
Phase 3, KEYNOTE-177
Conference
ASCO GI 2021

12 March, 2021 11:52

Circulating tumour DNA predicts recurrence in colorectal cancer

Presented By
Tenna Henriksen, Aarhus University, Denmark
Conference
ASCO GI 2021

12 March, 2021 11:48

Ipilimumab/nivolumab plus panitumumab in patients with microsatellite-stable mCRC

Presented By
Dr Michael Lee, University of Texas MD Anderson Cancer Center, USA
Trial
Phase 2
Conference
ASCO GI 2021

12 March, 2021 11:41

Predicting resistance to first-line FOLFOX plus bevacizumab in mCRC using circulating markers

Presented By
Prof. Thomas Seufferlein, University of Ulm, Germany
Trial
Phase 1/2, PERMAD
Conference
ASCO GI 2021

12 March, 2021 11:37

Final OS analyses comparing trifluridine/tipiracil + bevacizumab versus capecitabine + bevacizumab in first-line unresectable mCRC patients noneligible for intensive therapy

Presented By
Prof. Eric Van Cutsem, KU Leuven, Belgium
Trial
Phase 2, TASCO1
Conference
ASCO GI 2021

12 March, 2021 11:35

Maintenance treatment with cetuximab versus observation in RAS wildtype mCRC

Presented By
Dr Valérie Boige, Institut Gustave Roussy, France
Trial
Phase 2, PRODIGE 28-time UNICANCER
Conference
ASCO GI 2021

12 March, 2021 11:33

Duloxetine ameliorates oxaliplatin-induced peripheral neuropathy

Presented By
Dr Jeffrey Chi, Northwell Health Cancer Institute, NY, USA
Conference
ASCO GI 2021

12 March, 2021 11:31

Rechallenge of RAS/BRAF wildtype CRC with avelumab plus cetuximab

Conference
ESMO 2020

25 November, 2020 15:13

Surveillance after curative treatment for CRC

Conference
ESMO 2020

25 November, 2020 15:11

Adjuvant chemotherapy less effective in elderly CRC patients

Conference
ESMO 2020

25 November, 2020 15:10

CRC disseminates using collective migration

Conference
ESMO 2020

25 November, 2020 12:30

Post-colonoscopy colorectal cancers in IBD patients

Presented By
Ms Frederikke S. Troelsen, Aarhus University Hospital, Denmark
Conference
UEGW 2020

2 November, 2020 11:19

Mixed data: AMG 510 in tumours with KRASG12C

Presented By
Prof. Ramaswamy Govindan, Washington University, St Louis, USA
Conference
ESMO 2019

26 November, 2019 23:30

Liquid biopsy identifies relapse in patients with colorectal cancer after surgery

Presented By
Prof. Julien Taieb, Hopital European Georges Pompidou, France
Trial
Phase 3, IDEA-FRANCE
Conference
ESMO 2019

26 November, 2019 21:17

Advanced colorectal cancer and BRAF mutations: triplet combination improves survival

Presented By
Prof. Scott Kopetz, MD Anderson Cancer Center, Houston, USA
Trial
Phase 3, BEACON CRC
Conference
ESMO 2019

26 November, 2019 14:22

Global burden of digestive diseases reveals alarming trends

Trial
The Global Burden of Disease
Conference
UEGW 2019

23 October, 2019 17:46

IBD prevalence 3 times higher than estimated and expected to rise

Presented By
Dr Dominic King, University of Birmingham, UK
Conference
UEGW 2019

23 October, 2019 12:35

First-in-human study shows IL1RAP-targeting drug safe in solid tumours

Presented By
Dr Ahmad Awada, Institut Jules Bordet, Belgium
Conference
ASCO 2019

15 July, 2019 13:58

Long-term risk of advanced neoplasia after colonic low-grade dysplasia in IBD

Conference
ECCO 2018

28 May, 2018 23:13

Shallow whole-genome sequencing predicts future cancer risk of LGD in UC

Conference
ECCO 2018

28 May, 2018 21:30

Significantly increased risk of CRC and/or HGD after appendectomy in UC

Conference
ECCO 2018

28 May, 2018 18:43
site created by:   

© 2021 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy